DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy
Jacqueline V. Aredo(Stanford University), Jonathan W. Riess(University of California Davis Medical Center), Kavitha Ramchandran(Stanford University), Joel W. Neal(Stanford Medicine), Farshad Moradi(Stanford Medicine), Heather A. Wakelee(Palo Alto Institute), Millie Das(VA Palo Alto Health Care System), Carlos J. Suarez(Hospital Universitario Central de Asturias), Gerald J. Berry(Stanford University), Nathaniel J. Myall(Stanford University), Surbhi Singhal(International Society of Nephrology)
Cited by 1
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805